[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622978":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Galleri MCED Test","EXPERIMENTAL","Enrolled participants will complete:\n\n* Baseline visit with blood draw and questionnaires\n* Return of test results:\n\n  * For a positive result, diagnostic work-up could include clinic visits, biopsy, surgery, imaging assessments such as ultrasound, Computed Tomography (CT) scans, or Magnetic Resonance Imaging (MRI) scans. If standard, diagnostic work-up is positive or negative for cancer, follow up will be at the discretion of the principal investigator.\n  * For a negative MCED blood test with standard, diagnostic work-up that is negative, follow-up will be at the discretion of the principal investigator.\n* Online post-test questionnaire\n* Online post-diagnostic questionnaire\n* Follow up will be up to 24 months",[13],"Device: GRAIL Galleri MCED test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","GRAIL Galleri MCED test","A multi-cancer early detection (MCED) blood test.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Elizabeth O'Donnell, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","857-215-2361","Elizabeth_odonnell@dfci.harvard.edu",[31],{"facility":5,"status":20,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Boston","Massachusetts","02215","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-71.05977,42.35843,{"lat":41,"lon":40},[44,46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":45},"elizabeth_odonnell@dfci.harvard.edu",{"name":47,"role":24,"phone":20,"phoneExt":20,"email":20},"Elizabeth ODonnell, MD",{"type":24,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Elizabeth ODonnell","Principal Investigator","100622978","the-discover-study-100622978",false,"NCT07390643","The DISCOVER Study","Determining ImpactS of Multi-Cancer Early detectiOn Tests oVER Time in Symptomatic Patients: The DISCOVER Study","DISCOVERY","Inclusion Criteria:\n\n* Be at least 22 years old\n* Have signs and symptoms suggestive of cancer and\u002For have imaging related to signs and symptoms of cancer being evaluated in the Cancer Diagnostic Service clinic\n\nExclusion Criteria:\n\n* Individuals diagnosed with invasive malignancy within 3 years of enrollment\n* Individuals with active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast\u002Fprostate cancer is considered acceptable and will not preclude participation)",true,"ALL","22 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer.\n\nThe name of the screening blood test being studied is:\n\n-GRAIL Galleri MCED test",[70,71],"Cancer","Cancer Diagnosis",[70,71],"NOT_YET_RECRUITING","2026-02-02",{"date":76,"type":77},"2026-02-05","ACTUAL",{"date":79,"type":64},"2026-07",{"date":81,"type":64},"2028-01-31",{"name":5,"class":6},1]